[go: up one dir, main page]

WO2004006950A3 - Use of cd152 for treating autoimmune diseases and inflammations - Google Patents

Use of cd152 for treating autoimmune diseases and inflammations Download PDF

Info

Publication number
WO2004006950A3
WO2004006950A3 PCT/EP2003/007665 EP0307665W WO2004006950A3 WO 2004006950 A3 WO2004006950 A3 WO 2004006950A3 EP 0307665 W EP0307665 W EP 0307665W WO 2004006950 A3 WO2004006950 A3 WO 2004006950A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammations
autoimmune diseases
treating autoimmune
treating
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/007665
Other languages
German (de)
French (fr)
Other versions
WO2004006950A2 (en
Inventor
Monika Brunner-Weinzierl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charite Universitaetsmedizin Berlin
Original Assignee
Universitatsklinikum Charite Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitatsklinikum Charite Berlin filed Critical Universitatsklinikum Charite Berlin
Priority to DE10392933T priority Critical patent/DE10392933B4/en
Priority to AU2003250958A priority patent/AU2003250958A1/en
Publication of WO2004006950A2 publication Critical patent/WO2004006950A2/en
Publication of WO2004006950A3 publication Critical patent/WO2004006950A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed is the use of CD152, preferably CD152+ T cells, for treating autoimmune diseases and inflammations, particularly diseases associated with rheumatism.
PCT/EP2003/007665 2002-07-15 2003-07-15 Use of cd152 for treating autoimmune diseases and inflammations Ceased WO2004006950A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE10392933T DE10392933B4 (en) 2002-07-15 2003-07-15 Use of CD152, PD-1 (progressive cell death-1) or BTLA (B and T lymphocyte attenuator), particularly CD152-positive cells, for treatment, prevention and diagnosis of autoimmune diseases and inflammation
AU2003250958A AU2003250958A1 (en) 2002-07-15 2003-07-15 Use of cd152 for treating autoimmune diseases and inflammations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10232697A DE10232697A1 (en) 2002-07-15 2002-07-15 Use of CD152 for the treatment of autoimmune diseases and inflammation
DE10232697.5 2002-07-15

Publications (2)

Publication Number Publication Date
WO2004006950A2 WO2004006950A2 (en) 2004-01-22
WO2004006950A3 true WO2004006950A3 (en) 2004-06-10

Family

ID=30010180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007665 Ceased WO2004006950A2 (en) 2002-07-15 2003-07-15 Use of cd152 for treating autoimmune diseases and inflammations

Country Status (3)

Country Link
AU (1) AU2003250958A1 (en)
DE (2) DE10232697A1 (en)
WO (1) WO2004006950A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
EP3628322A1 (en) 2013-03-01 2020-04-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049318A1 (en) * 2000-01-03 2001-07-12 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
WO2001092337A2 (en) * 2000-05-26 2001-12-06 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10038722C2 (en) * 2000-08-09 2002-07-25 Genethor Gmbh Procedure for the reduction of specific immune reactions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049318A1 (en) * 2000-01-03 2001-07-12 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
WO2001092337A2 (en) * 2000-05-26 2001-12-06 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COX G N ET AL: "Refolding and Characterization of Recombinant Human Soluble CTLA-4 Expressed in Escherichia coli", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 17, no. 1, October 1999 (1999-10-01), pages 26 - 32, XP004441622, ISSN: 1046-5928 *
LEE KYUNG-MI ET AL: "Molecular basis of T cell inactivation by CTLA-4", SCIENCE (WASHINGTON D C), vol. 282, no. 5397, 18 December 1998 (1998-12-18), pages 2263 - 2266, XP002263896, ISSN: 0036-8075 *
SALOMON B ET AL: "COMPLEXITIES OF CD28/B7: CTLA-4 COSTIMULATORY PATHWAYS IN AUTOIMMUNITY AND TRANSPLANTATION", ANNUAL REVIEW OF IMMUNOLOGY, ANNUAL REVIEWS INC, US, vol. 19, 2001, pages 225 - 252, XP009004804, ISSN: 0732-0582 *

Also Published As

Publication number Publication date
DE10392933B4 (en) 2007-04-12
AU2003250958A1 (en) 2004-02-02
AU2003250958A8 (en) 2004-02-02
DE10392933D2 (en) 2005-07-14
DE10232697A1 (en) 2004-02-05
WO2004006950A2 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
AU2003285859A1 (en) Adaptive ophthalmologic system and method of using the same
AU2003216592A1 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
AU2003270169A1 (en) Human cd3-specific antibody with immunosuppressive properties
AU2003239159A1 (en) Placental derived stem cells and uses thereof
AU2003295818A1 (en) Antimicrobial lenses, processes to prepare them and methods of their use
AU2002953327A0 (en) Methods of diagnosing prognosing and treating activin associated diseases and conditions
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
UA86345C2 (en) Normal;heading 1;heading 2;USE OF OSTEOPROTEGERIN FOR THE PREVENTION AND/OR TREATMENT OF FIBROSIS
AU2003236211A1 (en) Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2004029214A8 (en) Lfa-1 alpha subunit antibodies and methods of use
AU2002363973A1 (en) Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
AU2002357644A1 (en) Therapeutic agents and corresponding treatments
AU2003235506A1 (en) Targeted enzymes and methods of making and using targeted enzymes.
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
WO2004006950A3 (en) Use of cd152 for treating autoimmune diseases and inflammations
AU2003222250A1 (en) Treatment of autoimmune diseases
AU2003256447A1 (en) Treatment of autoimmune skin diseases
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2003206285A1 (en) Unit and arrangement for the treatment of vehicles, where an integrated unit is used
AU2003215725A1 (en) Materials and methods relating to the treatment of lymphoma
AU2003217037A1 (en) Stem cell therapy
AU2003275127A1 (en) P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
AU2003304115A1 (en) Dinoflagellate karlotoxins, methods of isolation and uses thereof
AU2003249364A1 (en) Algal gdp-mannose-3',5'-epimerases and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REF Corresponds to

Ref document number: 10392933

Country of ref document: DE

Date of ref document: 20050714

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 10392933

Country of ref document: DE

122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8607

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP